Treatment
Cyclophosphamide clinical trials
We’re tracking 524 recruiting studies that include Cyclophosphamide, each written for real people, not researchers, below.
Recruiting studies
- NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Birmingham, AlabamaAges Up to 12 months - NCT07634471RecruitingPhase 2/Phase 3
Testing MK-1045 and Rituximab for Untreated Follicular Lymphoma
This trial tests a new drug called MK-1045 combined with rituximab (a standard lymphoma treatment) in people who have never been treated for follicular lymphoma. The goal is to see if this combination works better than current treatments.
Durham, North CarolinaAges 18 years+ - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Scottsdale, ArizonaAges 18 years+ - NCT04803201RecruitingPhase 2
Adding new drugs to usual treatment for peripheral T-cell lymphoma
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
Little Rock, ArkansasAges 18 years+ - NCT05876065Recruiting
Maintenance chemotherapy to help control advanced breast cancer
This trial studies whether taking a combination of capecitabine and cyclophosphamide after your best prior treatment can help keep advanced breast cancer from growing. It may help people whose disease has already responded or is stable after “salvage” treatment.
ShanghaiAges 18 years+ - NCT07565220RecruitingPhase 1
Thiotepa-based stem cell transplant for blood cancers
This trial tests a new chemotherapy preparation (using thiotepa) before a stem cell transplant from a matched donor to treat blood cancers like leukemia and myelodysplastic syndrome. The goal is to improve survival while reducing severe side effects.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07768436RecruitingPhase 2
cmf chemotherapy for breast cancer in older adults
This trial tests a combination of three older chemotherapy drugs (cyclophosphamide, methotrexate, and fluorouracil, called CMF) for adults 70 and older with breast cancer. The goal is to see if this treatment is effective and well-tolerated in this age group.
Basking Ridge, New JerseyAges 70 years+ - NCT07341867RecruitingPhase 1
Dose changes for cancer treatment in people with Duffy null
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Boston, MassachusettsAges 18 years+ - NCT07227584RecruitingPhase 2
ALL treatment for adolescents and young adults
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
Boston, MassachusettsAges 18–51 - NCT05225363RecruitingPhase 1
CAR T therapy for ovarian cancer that no longer responds to platinum
This Phase 1 study tests a one-time treatment made from your immune cells (CAR T) to attack a protein found on some ovarian cancer cells. It is for people whose ovarian cancer has come back or worsened after platinum chemotherapy, aiming to see safety and early signs of benefit.
Duarte, CaliforniaAges 18 years+ - NCT07764978RecruitingPhase 3
New drug combo for multiple myeloma without stem cell transplant
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT02621021RecruitingPhase 2
Immune cell therapy for advanced melanoma
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
Bethesda, MarylandAges 18–72 - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Newport Beach, CaliforniaAges 18–75 - NCT03630211RecruitingPhase 2
Study of stem cell transplant for systemic sclerosis in youth
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Pittsburgh, PennsylvaniaAges 8–60 - NCT06047171RecruitingPhase 2
Testing ALE.F02 for new kidney inflammation from vasculitis
This trial tests a new medicine called ALE.F02 for people newly diagnosed with a type of kidney inflammation called rapidly progressive glomerulonephritis (RPGN) caused by ANCA vasculitis. The goal is to see if it can help rescue kidney function.
PragueAges 18 years+ - NCT06186401RecruitingPhase 1
Experimental immune cell therapy for a specific type of brain cancer
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT06897930RecruitingPhase 1/Phase 2
Testing a new drug for adults with lupus
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
San Francisco, CaliforniaAges 18–70 - NCT06236139RecruitingPhase 1/Phase 2
Immune cells plus hormone therapy for advanced prostate cancer
This study tests a new type of treatment that uses your own immune cells (engineered to target prostate cancer) combined with a hormone therapy drug. It is for men with advanced prostate cancer that has stopped responding to standard hormone treatments.
Seattle, WashingtonAges 18 years+ - NCT07479797RecruitingPhase 3
Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
Goodyear, ArizonaAges 18 years+ - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT06940297RecruitingPhase 2
Dasatinib and quercetin with Carvykti for advanced multiple myeloma
This trial tests whether adding two drugs (dasatinib and quercetin) before CAR-T therapy (Carvykti) can improve outcomes for people with multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this combination is safe and effective.
Rochester, MinnesotaAges 18 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Birmingham, AlabamaAges 5–60 - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Birmingham, AlabamaAges Up to 30 years - NCT06486051RecruitingPhase 2
CAR T-cell therapy for adults with relapsed large B-cell lymphoma
This trial tests a new treatment called atlacabtagene autoleucel, which uses your own immune cells to fight the lymphoma. It's designed for people whose lymphoma has come back or not responded to initial treatments.
Auckland, AucklandAges 18–75
Common questions
- Are there clinical trials studying Cyclophosphamide?
- Yes. Clin2 currently lists 524 recruiting studies that include Cyclophosphamide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cyclophosphamide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cyclophosphamide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cyclophosphamide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.